Get the Stockscreener App
10.08
2.44%
0.24
Bridgebio Oncology Therapeutics Inc stock is traded at $10.08, with a volume of 298.28K.
It is up +2.44% in the last 24 hours and up +0.00% over the past month.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
See More
Previous Close:
$9.84
Open:
$10.1
24h Volume:
298.28K
Relative Volume:
7.56
Market Cap:
$758.70M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+6.67%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.70
$10.51
1-Week Range:
$8.79
$10.51
52-Week Range:
$8.70
$12.50
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Name
Bridgebio Oncology Therapeutics Inc
Sector
Industry
Phone
857 702 0377
Address
C/O CORMORANT ASSET MANAGEMENT, LP, BOSTON
Compare BBOT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
10.08 | 758.70M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Initiated | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Latest News
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com
Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target - MarketScreener
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - MSN
BridgeBio Oncology Therapeutics shares rise 4.57% after-hours after announcing participation in September investor conferences. - AInvest
BBOT to Participate in Upcoming September Investor Healthcare Conferences - The Manila Times
BBOT to Participate in Upcoming September Investor Healthcare Conferences - GlobeNewswire Inc.
BridgeBio's Strategy To Unleash The Full Potential Of RASDrugging The Undruggable - RTTNews
BridgeBio Oncology Therapeutics shares rise 11.34% premarket after Wedbush initiates coverage. - AInvest
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
We're Hopeful That BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Will Use Its Cash Wisely - Yahoo Finance
We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth - simplywall.st
BridgeBio Oncology Therapeutics shares rise 1.17% intraday after Piper Sandler initiates coverage. - AInvest
Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target - MarketScreener
BridgeBio Oncology initiated with an Overweight at Piper Sandler - TipRanks
Bridgebio Oncology Therapeutics, Inc. shares rise 2.12% intraday after Helix Acquisition Corp. II retains more than 60% of trust account. - AInvest
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Australia
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating - Investing.com
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - MarketScreener
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer - Business Wire
Helix Acquisition Corp. II Clears SEC Hurdle for BBOT Business Combination - Stock Titan
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
Boston SPAC picks biotech to take public - The Business Journals
Seven biotech spinouts to watch out for in 2025 - Labiotech.eu
BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC - OncLive
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS - Business Wire
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - BioSpace
BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRASG12C Mutant Tumors - BioSpace
Unnatural Products Announces BridgeBio Exercises Option to - GlobeNewswire
BridgeBio Oncology Therapeutics Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - MarketScreener
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Business Wire
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer - Business Wire
BridgeBio launches another new company, GondolaBio - The Pharma Letter
BridgeBio forms another offshoot with $300M in commitments - Endpoints News
How Computer-Aided Drug Discovery Is Leading to Revolutionary Cancer Treatment - Tech Briefs
Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout - Fierce Biotech
BridgeBio Pharma spins out cancer-focused unit with three drugs, $200 millionSan Francisco Business Times - The Business Journals
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner - GlobeNewswire
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn - GlobeNewswire
BridgeBio Acquires Remaining Stake in Eidos to Tune of $175 Million - BioSpace
BridgeBio - Crunchbase
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Financials Data
There is no financial data for Bridgebio Oncology Therapeutics Inc (BBOT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):